Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Universal Ibogaine Inc ( (TSE:IBO) ) is now available.
Universal Ibogaine Inc. has closed the sale of its Belize property for USD 300,000, finalizing the transfer of its wholly-owned subsidiary, Universal Ibogaine Belize Ltd., which holds 20 acres of undeveloped land. The transaction, involving company director Thomas Vidrine, was approved by disinterested shareholders and met TSX Venture Exchange regulatory requirements, potentially impacting the company’s financial flexibility and strategic focus on its core addiction treatment initiatives.
More about Universal Ibogaine Inc
Universal Ibogaine Inc. is a life sciences company focused on revolutionizing addiction treatment through medicalized ibogaine. The company aims to tackle opioid use disorder with planned clinical trials in Canada and intends to expand its protocols globally through future licensing agreements. Additionally, UI is developing a comprehensive addiction treatment protocol at the Kelburn Recovery Centre in Manitoba, Canada.
YTD Price Performance: 100.0%
Average Trading Volume: 161,324
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$5.5M
For an in-depth examination of IBO stock, go to TipRanks’ Stock Analysis page.
